Status: Not yet recruiting

Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI

This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).

Participants needed: 24

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Sep 14, 2026Locations: 1

Eligibility criteria

≥1 prior line of therapy before BTKi [+9]

Active CNS involvement [+4]

Status: Recruiting

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.

Participants needed: 30

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 20, 2026Locations: 1

Eligibility criteria

Confirmed diagnosis of mantle cell lymphoma by hematopathology. MCL should have... [+3]

Isolated bone marrow or GI only disease MCL participants and/or lack of any meas... [+43]

Status: Recruiting

Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL

This is a multi-center, prospective cohort study. The main purpose of study is to evaluate the efficacy and safety of Orelabrutinib combined with Zuberitamab in the initial treatment of MZL Main efficacy indicators Complete response rate (CR) at the end of combination therapy.

Participants needed: 33

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Li ZhimingUpdated: May 22, 2025Locations: 2

Eligibility criteria

ANC>1.0×109/L; [+5]

Patients with central nervous system invasion; [+14]